Capital Fund Management (CFM)’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-51,161
| Closed | -$10.1M | – | 2079 |
|
|
2026
Q1 | $10.1M | Buy |
+51,161
| New | +$9.86M | 0.05% | 552 |
|
|
2025
Q3 | – | Sell |
-7,549
| Closed | -$1.14M | – | 2431 |
|
|
2025
Q2 | $1.06M | Sell |
7,549
-8,778
| -54% | -$1.23M | ﹤0.01% | 1984 |
|
|
2025
Q1 | $2.4M | Sell |
16,327
-122,030
| -88% | -$17.7M | 0.01% | 1338 |
|
|
2024
Q4 | $18.1M | Buy |
+138,357
| New | +$19.4M | 0.05% | 517 |
|
|
2024
Q3 | – | Sell |
-15,692
| Closed | -$2.53M | – | 1975 |
|
|
2024
Q2 | $2.45M | Sell |
15,692
-166,292
| -91% | -$25M | 0.01% | 1288 |
|
|
2024
Q1 | $24.7M | Sell |
181,984
-116,890
| -39% | -$15.5M | 0.07% | 358 |
|
|
2023
Q4 | $40.3M | Buy |
298,874
+146,810
| +97% | +$19.1M | 0.11% | 263 |
|
|
2023
Q3 | $20.6M | Buy |
+152,064
| New | +$20.8M | 0.07% | 349 |
|
|
2022
Q4 | – | Sell |
-154,042
| Closed | -$19.3M | – | 1400 |
|
|
2022
Q3 | $16.9M | Buy |
154,042
+101,392
| +193% | +$12.9M | 0.13% | 197 |
|
|
2022
Q2 | $6.96M | Buy |
+52,650
| New | +$6.91M | 0.06% | 421 |
|
|
2021
Q1 | – | Sell |
-32,727
| Closed | -$3.27M | – | 1264 |
|
|
2020
Q4 | $3.27M | Buy |
+32,727
| New | +$3.47M | 0.03% | 613 |
|
|
2020
Q3 | – | Sell |
-22,385
| Closed | -$2.37M | – | 1191 |
|
|
2020
Q2 | $2.37M | Sell |
22,385
-27,139
| -55% | -$2.8M | 0.04% | 451 |
|
|
2020
Q1 | $4.42M | Buy |
49,524
+30,141
| +156% | +$2.84M | 0.07% | 328 |
|
|
2019
Q4 | $1.93M | Buy |
+19,383
| New | +$1.82M | 0.02% | 851 |
|
|
2019
Q2 | – | Sell |
-4,026
| Closed | -$326K | – | 1592 |
|
|
2019
Q1 | $326K | Buy |
+4,026
| New | +$317K | ﹤0.01% | 1417 |
|
|
2016
Q1 | – | Sell |
-6,559
| Closed | -$445K | – | 1507 |
|
|
2015
Q4 | $445K | Buy |
+6,559
| New | +$430K | ﹤0.01% | 1163 |
|
|
2015
Q2 | – | Sell |
-110,789
| Closed | -$7.58M | – | 1454 |
|
|
2015
Q1 | $7.58M | Sell |
110,789
-199,683
| -64% | -$13.9M | 0.1% | 248 |
|
|
2014
Q4 | $21.9M | Buy |
310,472
+174,627
| +129% | +$12.5M | 0.26% | 95 |
|
|
2014
Q3 | $9.71M | Buy |
135,845
+121,347
| +837% | +$8.88M | 0.11% | 228 |
|
|
2014
Q2 | $1.08M | Sell |
14,498
-302
| -2% | -$21.8K | 0.01% | 936 |
|
|
2014
Q1 | $960K | Buy |
+14,800
| New | +$956K | 0.01% | 973 |
|
|
2013
Q3 | – | Sell |
-160,281
| Closed | -$8.05M | – | 1565 |
|
|
2013
Q2 | $7.58M | Buy |
+160,281
| New | +$8.16M | 0.12% | 220 |
|
Other funds holding AZN
EP
IA
Capital Fund Management (CFM)'s AZN Position: Q2 2026 in Review
Capital Fund Management (CFM) sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 51,161 shares — an estimated $10.1M sold.
Capital Fund Management (CFM) first reported a position in AZN in Q2 2013 and held it in 22 quarters. The position peaked at $40.3M in Q4 2023. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Capital Fund Management (CFM) reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
- Capital Fund Management (CFM) sold 51,161 AstraZeneca shares in Q2 2026, an estimated $10.1M.
- Capital Fund Management (CFM) first reported a position in AstraZeneca in Q2 2013 and held it in 22 quarters.
- Capital Fund Management (CFM)'s AstraZeneca position peaked at $40.3M in Q4 2023.
- 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.